173 related articles for article (PubMed ID: 31208461)
1. Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.
Zhao Q; Hu J; Mitra A; Cutrera J; Zhang W; Zhang Z; Yan J; Xia X; Mahadeo KM; Livingston JA; Gorlick R; Li S
J Immunother Cancer; 2019 Jun; 7(1):154. PubMed ID: 31208461
[TBL] [Abstract][Full Text] [Related]
2. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
[TBL] [Abstract][Full Text] [Related]
3. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
4. Bempegaldesleukin (BEMPEG; NKTR-214) efficacy as a single agent and in combination with checkpoint-inhibitor therapy in mouse models of osteosarcoma.
Hennessy M; Wahba A; Felix K; Cabrera M; Segura MG; Kundra V; Ravoori MK; Stewart J; Kleinerman ES; Jensen VB; Gopalakrishnan V; Pena R; Quach P; Kim G; Kivimäe S; Madakamutil L; Overwijk WW; Zalevsky J; Gordon N
Int J Cancer; 2021 Apr; 148(8):1928-1937. PubMed ID: 33152115
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
Kawano M; Itonaga I; Iwasaki T; Tsumura H
Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
[TBL] [Abstract][Full Text] [Related]
6. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors.
Hu J; Yang Q; Zhang W; Du H; Chen Y; Zhao Q; Dao L; Xia X; Natalie Wall F; Zhang Z; Mahadeo K; Gorlick R; Kopetz S; Dotti G; Li S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35027427
[TBL] [Abstract][Full Text] [Related]
7. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S; Smeltz RB; Nanajian A; Heller R
Front Immunol; 2020; 11():614667. PubMed ID: 33628206
[TBL] [Abstract][Full Text] [Related]
8. T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.
Hu J; Sun C; Bernatchez C; Xia X; Hwu P; Dotti G; Li S
Clin Cancer Res; 2018 Jun; 24(12):2920-2934. PubMed ID: 29391351
[No Abstract] [Full Text] [Related]
9. Combination immunotherapy using G-CSF and oncolytic virotherapy reduces tumor growth in osteosarcoma.
Morales-Molina A; Gambera S; Leo A; García-Castro J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737338
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical toxicity assessment of tumor-targeted interleukin-12 low-intensity electrogenetherapy.
Reed SD; Li S
Cancer Gene Ther; 2011 Apr; 18(4):265-74. PubMed ID: 21233859
[TBL] [Abstract][Full Text] [Related]
11. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
[TBL] [Abstract][Full Text] [Related]
12. The immunocytokine NHS-IL12 as a potential cancer therapeutic.
Fallon J; Tighe R; Kradjian G; Guzman W; Bernhardt A; Neuteboom B; Lan Y; Sabzevari H; Schlom J; Greiner JW
Oncotarget; 2014 Apr; 5(7):1869-84. PubMed ID: 24681847
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
Jian C; Tu MJ; Ho PY; Duan Z; Zhang Q; Qiu JX; DeVere White RW; Wun T; Lara PN; Lam KS; Yu AX; Yu AM
Oncotarget; 2017 May; 8(19):30742-30755. PubMed ID: 28415566
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells.
Jovanovic IP; Pejnovic NN; Radosavljevic GD; Pantic JM; Milovanovic MZ; Arsenijevic NN; Lukic ML
Int J Cancer; 2014 Apr; 134(7):1669-82. PubMed ID: 24105680
[TBL] [Abstract][Full Text] [Related]
16. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
Nair RE; Kilinc MO; Jones SA; Egilmez NK
J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
[TBL] [Abstract][Full Text] [Related]
17. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
[TBL] [Abstract][Full Text] [Related]
18. Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models.
Hu J; Lazar AJ; Ingram D; Wang WL; Zhang W; Jia Z; Ragoonanan D; Wang J; Xia X; Mahadeo K; Gorlick R; Li S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38199607
[TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12.
Cavallo F; Signorelli P; Giovarelli M; Musiani P; Modesti A; Brunda MJ; Colombo MP; Forni G
J Natl Cancer Inst; 1997 Jul; 89(14):1049-58. PubMed ID: 9230887
[TBL] [Abstract][Full Text] [Related]
20. IL-10 elicits IFNγ-dependent tumor immune surveillance.
Mumm JB; Emmerich J; Zhang X; Chan I; Wu L; Mauze S; Blaisdell S; Basham B; Dai J; Grein J; Sheppard C; Hong K; Cutler C; Turner S; LaFace D; Kleinschek M; Judo M; Ayanoglu G; Langowski J; Gu D; Paporello B; Murphy E; Sriram V; Naravula S; Desai B; Medicherla S; Seghezzi W; McClanahan T; Cannon-Carlson S; Beebe AM; Oft M
Cancer Cell; 2011 Dec; 20(6):781-96. PubMed ID: 22172723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
